新型PET示踪剂:肺癌中的现有知识与前景展望
本文综述了近十年PubMed与clinicaltrials.gov上关于肺癌新型PET示踪剂的研究,排除病例报告、临床前研究及[18F]FDG和DOTATE等成熟示踪剂。多种靶向肿瘤特征和癌症标志的示踪剂已被开发,少数与[18F]FDG-PET/CT进行了头对头比较。目前尚无示踪剂可替代[18F]FDG-PET/CT,但可能作为补充成像方法提供肿瘤生物学特征及瘤内和瘤间异质性信息。
要点
- 目前尚无新型PET示踪剂可替代[18F]FDG-PET/CT用于肺癌。
- 少数示踪剂已与[18F]FDG-PET/CT进行头对头评估。
- 部分示踪剂可能作为补充成像方法显示肿瘤生物学特征与异质性。
核心结论
- 目前尚无任何示踪剂可替代[18F]FDG-PET/CT,但部分示踪剂可能作为补充成像方法提供肿瘤生物学特征及瘤内和瘤间异质性信息。
研究设计与样本
- 本综述在PubMed和clinicaltrials.gov进行文献检索,限定近十年,排除病例报告、临床前研究及[18F]FDG和DOTATE等成熟示踪剂的研究,并对检索出的最相关论文进行评估。
主要发现
- 多种示踪剂已针对特定肿瘤特征和癌症标志被开发。
- 少数示踪剂已被广泛研究并与[18F]FDG-PET/CT进行头对头评估,而其他示踪剂需进一步研究和在更大临床试验中验证。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文指出其他示踪剂需进一步研究和在更大临床试验中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PET/CT with the tracer 2-[18F]fluoro-2-deoxy-D-glucose ([18F]FDG) has improved diagnostic imaging in cancer and is routinely used for diagnosing, staging and treatment planning in lung cancer patients. However, pitfalls of [18F]FDG-PET/CT limit the use in specific settings. Additionally, lung cancer is still the leading cause of cancer associated death and has high risk of recurrence after curative treatment. These circumstances have led to the continuous search for more sensitive and specific PET tracers to optimize lung cancer diagnosis, staging, treatment planning and evaluation. The objective of this review is to present and discuss current knowledge and perspectives of new PET tracers for use in lung cancer. A literature search was performed on PubMed and clinicaltrials.gov, limited to the past decade, excluding case reports, preclinical studies and studies on established tracers such as [18F]FDG and DOTATE. The most relevant papers from the search were evaluated. Several tracers have been developed targeting specific tumor characteristics and hallmarks of cancer. A small number of tracers have been studied extensively and evaluated head-to-head with [18F]FDG-PET/CT, whereas others need further investigation and validation in larger clinical trials. At this moment, none of the tracers can replace [18F]FDG-PET/CT. However, they might serve as supplementary imaging methods to provide more knowledge about biological tumor characteristics and visualize intra- and inter-tumoral heterogeneity.
引用
- Krarup MMK, Fischer BM, Christensen TN, et al. New PET Tracers: Current Knowledge and Perspectives in Lung Cancer. Semin Nucl Med. 2022. PMID: 35752465. doi:10.1053/j.semnuclmed.2022.05.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。